Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Intranasal MV-014-212 COVID-19 Vaccine in Healthy Adults
NCT04798001Phase 1Unknown
- Sponsor
- Meissa Vaccines
- Start
- Apr 2021
- Primary completion
- Oct 2022
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MV-014-212 in coronavirus disease 2019 (COVID-19) (8 cohorts), sponsored by Meissa Vaccines. Primary endpoints: Solicited adverse events, Unsolicited adverse events and 3 more. Status: unknown.
02
Drugs
MV-014-212
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04798001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798001.